Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study

Key Points

Cholestatic jaundice occurred in 1.52% of tuberculosis patients, indicating a significant risk.
Older age and low BMI were identified as key risk factors for developing jaundice.
The observational analysis highlights the need for early liver monitoring among high-risk groups.
Support for individualized management ensures safe and effective treatment of tuberculosis patients.

Abstract

Rifampicin-induced cholestatic jaundice was observed in 1.52% of TB patients. Older age (≥60 years) and low BMI (2) were identified as key risk factors.Early liver monitoring is essential in high-risk groups. Most patients tolerated rifampicin rechallenge, supporting individualized, risk-based management to ensure safe and effective TB treatment.

Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study

Key Points

Abstract

Cite This Study